We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
16 August 2017
The Canadian Agency for Drugs and Technologies in Health (CADTH) recently sought feedback on a proposal to permit revisions to existing Canadian Drug Expert Committee (CDEC) recommendations made through the common drug review process during the therapeutic review process, eliminating the need to update recommendations through the request for advice process. The consultation period closed on August 11 2017.
During the therapeutic review process, the CDEC will consider whether any recommendations should be revised. Manufacturers will be notified at the initial therapeutic review stage of:
There will be no embargo period. A formal reconsideration process will not be available, but manufacturers may provide stakeholder feedback. Their input will be considered before finalising the revised recommendations, which will occur at the meeting to finalise the therapeutic review recommendations.
For further information on this topic please contact Daphne Lainson at Smart & Biggar/Fetherstonhaugh by telephone (+1 613 232 2486) or email (email@example.com). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.